SHORT SUMMARY
The article, “Material Informatics-Driven Insights into Brain Cancer Nanocarriers: A Bibliometric Comparison of PLGA vs. Liposomes,” explores the role of material informatics in optimizing nanocarriers for brain cancer treatment. It compares PLGA nanoparticles and liposomes, emphasizing their distinct strengths—biodegradability for PLGA and superior drug encapsulation for liposomes. Material informatics tools, including machine learning and computational modeling, are highlighted as transformative in improving drug delivery across the blood-brain barrier (BBB).
Key findings include:
- PLGA is effective for sustained drug release with targeted delivery capabilities.
- Liposomes excel in encapsulating both hydrophilic and hydrophobic drugs, with functionalization options enhancing targeting precision.
- Material informatics significantly aids in optimizing drug release kinetics, stability, and biocompatibility.
The bibliometric analysis uses Scopus data and VOSviewer to identify trends, collaboration networks, and gaps in the literature. While PLGA research focuses on biodegradability and biological interactions, liposome studies emphasize encapsulation efficiency and stability. The integration of material informatics into nanocarrier design is presented as a critical advancement for brain cancer therapies. Recommendations for future research include leveraging AI for personalized medicine and addressing BBB variability to enhance treatment outcomes.
Who Can Benefit from This Research?
- Medical Researchers: The insights can guide the development of innovative nanocarrier-based drug delivery systems, particularly for glioblastoma and other brain cancers, using data-driven methodologies like material informatics.
- Pharmaceutical Industry: Companies can use the findings to optimize nanocarrier design (e.g., PLGA nanoparticles and liposomes) for enhanced drug delivery across the blood-brain barrier (BBB), paving the way for more effective brain cancer treatments.
- Clinicians: Healthcare professionals involved in cancer therapy can leverage nanocarrier technologies to improve treatment outcomes for patients with brain cancer, particularly by utilizing personalized medicine approaches.
- Patients: Brain cancer patients, particularly those with aggressive forms like glioblastoma, can benefit from improved treatment efficacy, reduced systemic toxicity, and more tailored therapies.
- Material Scientists and AI Specialists: The study highlights the role of material informatics and AI in optimizing drug delivery systems, opening new avenues for interdisciplinary collaboration and technological advancement.
- Policy Makers and Regulators: Understanding the regulatory challenges and advancements in nanocarrier technology can aid in formulating guidelines for the safe and effective use of these systems in clinical settings.
